Results 61 to 70 of about 9,036,291 (122)

Acute non-lymphocytic leukemia following Hodgkin's disease. Clinical, biological and cytogenetic aspect of three cases.

open access: yes, 1979
In a groups of 254 patients treated for Hodgkin's disease with a follow up period of minimum 2 years, 3 cases of acute non lymphoid leukaemia (ANLL) were observed: erythroleukaemia, myelomonocytic and myeloblastic leukaemia, respectively.
ALIMENA, Giuliana   +8 more
core  

Mitoxantrone, etoposide and intermediate dose Ara-C combination chemotherapy protocol in resistance of recurrent ANLL Direncli veya yineleyen anll'de mitoxantrone, etoposide ve orta doz Ara-C kemoterapi protokolu

open access: yes, 1997
Background and Design. Intensive sequential chemotherapy with mitoxantrone 12 mg/m2/d on days 1 through 3; etoposide 200 mg/m2/d as a continuous infusion on days 8 through 10, cytarabine (Ara-C) 500 mg/m2/d as a continuous infusion on days 1 through 3 ...
Ulku, B.   +7 more
core  

Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy. [PDF]

open access: yesNAR Cancer, 2023
Anand J   +7 more
europepmc   +1 more source

POP and MRP overexpressions are negative prognostic factor on anll

open access: yes, 1997
By flow cytometry, the P-glycoprotein (PGP), the Lung Resistance-related Protein (LRP) and the Multidrug Resistance associated Protein (MRP) expressions and the blast cells' Intracellular Daunombicin Accumulation (IDA) were evaluated in 91 de Novo Acute ...
Eimaccra A.   +11 more
core  

Influence of cholesterol on cancer progression and therapy. [PDF]

open access: yesTransl Oncol, 2021
Mayengbam SS   +3 more
europepmc   +1 more source

Acute monocytic leukemia: A myeloid leukemia subset that may be sensitive to methotrexate

open access: yes, 1995
Impaired polyglutamylation of methotrexate (MTX) and thus poor retention is believed to be the basis of intrinsic resistance in blasts from patients with acute myeloid leukemia (AML) to MTX.
Banerjee D.   +6 more
core  

Home - About - Disclaimer - Privacy